Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus NephritisActive Not Recruiting
NCT04221477Phase 3Updated Jul 21, 2026
Sponsor: Hoffmann-La Roche
Lupus Nephritis
United States, Argentina, Brazil, Colombia, France +10 more
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung CancerTerminated
NCT03445000Phase 2Updated Jul 21, 2026
Sponsor: ETOP IBCSG Partners Foundation
Non-small Cell Lung Cancer · Non-small Cell Lung Cancer Metastatic · Non-small Cell Lung Cancer Recurrent
Belgium, Ireland, Italy, Netherlands, Spain +1 more
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Active Not Recruiting
NCT04861259Phase 3Updated Jul 21, 2026
Sponsor: Hoffmann-La Roche
Atypical Hemolytic Uremic Syndrome
United States, Belgium, Brazil, Canada, China +11 more
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseaseNot Yet Recruiting
NCT07717411Phase 3Updated Jul 21, 2026
Sponsor: Hoffmann-La Roche
Alzheimer's Disease
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)Recruiting
NCT04929223Phase 1Updated Jul 20, 2026
Sponsor: Hoffmann-La Roche
Metastatic Colorectal Cancer
United States, Australia, Canada, Denmark, Germany +6 more
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesRecruiting
NCT07351045Phase 3Updated Jul 20, 2026
Sponsor: Hoffmann-La Roche
Obesity or Overweight
United States, Argentina, Australia, Belgium, Brazil +14 more
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple SclerosisSuspended
NCT05949580N/AUpdated Jul 20, 2026
Sponsor: Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
United States, Germany, Spain
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's LymphomaRecruiting
NCT06806033Phase 2Updated Jul 20, 2026
Sponsor: Hoffmann-La Roche
B-Cell Non-Hodgkins Lymphoma
United States, Australia, Canada, France, Germany +2 more
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic RetinopathyRecruiting
NCT07588100Phase 1Updated Jul 20, 2026
Sponsor: Hoffmann-La Roche
Diabetic Retinopathy
United States
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruiting
NCT07555938Phase 3Updated Jul 20, 2026
Sponsor: Hoffmann-La Roche
Multiple Myeloma
United States, Japan, Puerto Rico, South Korea
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung CancerCompleted
NCT05775289Phase 2Updated Jul 20, 2026
Sponsor: Hoffmann-La Roche
Non-small Cell Lung Cancer
United States, Australia, Belgium, Brazil, France +6 more
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesRecruiting
NCT07351058Phase 3Updated Jul 20, 2026
Sponsor: Hoffmann-La Roche
Obesity or Overweight · Type 2 Diabetes Mellitus
United States, Argentina, Australia, Canada, China +14 more
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)Recruiting
NCT07282574Phase 2Updated Jul 20, 2026
Sponsor: Hoffmann-La Roche
Progressive Multiple Sclerosis
Australia, France, Germany, Hungary, Italy +6 more
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationCompleted
NCT01867125Phase 3Updated Jul 17, 2026
Sponsor: Hoffmann-La Roche
Asthma
United States, Argentina, Australia, Belgium, Canada +21 more
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative ColitisCompleted
NCT04090411Phase 2Updated Jul 17, 2026
Sponsor: Hoffmann-La Roche
Moderate to Severe Ulcerative Colitis
United States, Australia, Belgium, Bulgaria, Colombia +18 more
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeRecruiting
NCT07284121N/AUpdated Jul 17, 2026
Sponsor: Hoffmann-La Roche
Lung Cancer, Hepatocellular Carcinoma
Austria, Belgium, Bulgaria, Italy, Poland +3 more
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate AsthmaCompleted
NCT02104674Phase 3Updated Jul 17, 2026
Sponsor: Hoffmann-La Roche
Asthma
United States, Brazil, Bulgaria, Canada, Czechia +6 more
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active Not Recruiting
NCT05296798Phase 3Updated Jul 16, 2026
Sponsor: Hoffmann-La Roche
Locally Advanced or Metastatic Breast Cancer
United States, Argentina, Belgium, Brazil, China +24 more
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Recruiting
NCT04524871Phase 1, Phase 2Updated Jul 16, 2026
Sponsor: Hoffmann-La Roche
Advanced Liver Cancers
United States, China, France, Israel, New Zealand +2 more
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruiting
NCT07054190Phase 2Updated Jul 16, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Brazil, Canada, Germany +2 more
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative ColitisRecruiting
NCT07158242Phase 3Updated Jul 16, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Ulcerative Colitis
United States, Australia, China, South Africa, Taiwan +2 more
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)Recruiting
NCT05652686Phase 1, Phase 2Updated Jul 15, 2026
Sponsor: Phanes Therapeutics
Small Cell Lung Cancer (SCLC) · Large Cell Neuroendocrine Cancer (LCNEC) · Neuroendocrine Prostate Cancer (NEPC) · Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruiting
NCT03424005Phase 1, Phase 2Updated Jul 15, 2026
Sponsor: Hoffmann-La Roche
Metastatic Breast Cancer
United States, Australia, France, Germany, Israel +4 more
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin AmericaActive Not Recruiting
NCT04158258N/AUpdated Jul 15, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
Argentina, Brazil, Chile, Colombia, Cuba +5 more
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver FibrosisActive Not Recruiting
NCT06903065Phase 1Updated Jul 15, 2026
Sponsor: Hoffmann-La Roche
MASH
United States, Mexico, Puerto Rico

Previous page Next page